23 completed. 23 Phase 2, 8 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 23 | Completed 23 |
| Phase 3 | 8 | Completed 8 |
| Phase 1 | 1 | Completed 1 |
Follow Duodenal Diseases: new trials by email Literature Review of Duodenal Diseases trials Research Report on Duodenal Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Safety and Efficacy of X842 in Patients With Reflux Esophagitis X842, X842 Placebo, Lansoprazole - Reflux Esophagitis | Phase 2 | Completed | Jiangsu Sinorda Biomedicine Co., Ltd | 90 | 2020-01-21 | 2025-07-17 |
| To Compare the Gastrointestinal Safety of a 14-Day Oral Dosing Regimen of ATB-346 to Sodium Naproxen in Healthy Subjects ATB-346 OR Placebo, Naproxen sodium - Gastric Ulcer | Phase 1 / Phase 2 | Completed | Antibe Therapeutics Inc. | 258 | 2017-09-08 | 2018-06-06 |
| To Evaluate Efficacy and Safety of Z-215 in Erosive Esophagitis Z-215 10mg, Z-215 20mg, Z-215 Placebo - Esophagitis, Reflux | Phase 2 | Completed | Zeria Pharmaceutical | 503 | 2015-05-01 | 2017-07-02 |
| Efficacy and Safety of PMK-S005 in the Prevention of Recurrent Peptic Ulcer in Low-dose Aspirin Users Placebo, PMK-S005 1, PMK-S005 2 - Peptic Ulcer | Phase 2 | Completed | PharmaKing | 88 | 2014-11-24 | 2018-01-23 |
| Cytoprotective Agent and Peptic Ulcer in Dual Antiplatelet :RCT Repamipide, Placebo - Gastric Ulcer Induced by Anti-platelet Agent, Duodenal Ulcer Induced by Anti-platelet Agent | Phase 2 / Phase 3 | Completed | King Chulalongkorn Memorial Hospital | 142 | 2014-07-01 | 2019-02-27 |
| Residual Gastric Volume After the Ingestion of a Beverage Containing Carbohydrates Plus Whey Protein Carbohydrate plus whey protein enriched drink - Peptic Ulcer, Gastritis | Phase 2 / Phase 3 | Completed | Federal University of Mato Grosso | 30 | 2013-02-01 | 2013-04-10 |
| Study to Investigate the Safety, Tolerability and Efficacy of YH4808 in Patients With Reflux Esophagitis Esomeprazole 40mg, YH4808 A mg, YH4808 B mg - Reflux Esophagitis | Phase 2 | Completed | Yuhan Corporation | 154 | 2012-12-01 | 2014-07-10 |
| Long-term Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study) Rabeprazole - Gastric Ulcers Duodenal Ulcers Caused by Low-dose Aspirin | Phase 2 / Phase 3 | Completed | Eisai Co., Ltd. | 405 | 2011-12-01 | 2015-12-21 |
| Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study) E3810, Teprenone - Gastric or Duodenal Ulcers Caused by Low-dose Aspirin | Phase 2 / Phase 3 | Completed | Eisai Co., Ltd. | 472 | 2011-07-01 | 2014-11-26 |
| Rates of Gastric Ulcer by Endoscopy in Knee Osteoarthritis Patients Receiving LT-NS001 Versus Naprosyn® LT-NS001, Naprosyn® - Osteoarthritis | Phase 2 / Phase 3 | Completed | Logical Therapeutics | 534 | 2010-02-01 | 2011-01-24 |
| Prevention of Progression of Duodenal Adenomas in Patients With Familial Adenomatous Polyposis Celecoxib, Ursodeoxycholic acid, Placebo - Familial Adenomatous Polyposis, Duodenal Neoplasms | Phase 2 / Phase 3 | Completed | Radboud University Medical Center | 37 | 2009-05-01 | 2013-05-16 |
| Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis E3810 - Refractory Reflux Esophagitis | Phase 2 / Phase 3 | Completed | Eisai Co., Ltd. | 337 | 2008-10-01 | 2012-04-18 |
| Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients 5 mg ilaprazole, 10 mg ilaprazole, 10 mg Rabeprazole - Duodenal Ulcer | Phase 2 / Phase 3 | Completed | Livzon Pharmaceutical Group Inc. | 408 | 2008-08-01 | 2016-07-28 |
| Efficacy of Proton Pump Inhibitor in Prevention of Clopidogrel-related Peptic Ulcer esomeprazole - Peptic Ulcer | Phase 2 | Completed | Kaohsiung Veterans General Hospital. | 165 | 2008-08-01 | 2015-09-09 |
| Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer Laboratory Biomarker Analysis, Pazopanib Hydrochloride, Pharmacological Study - Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor | Phase 2 | Completed | National Cancer Institute (NCI) | 52 | 2007-03-01 | 2020-04-03 |
| Capecitabine and Temozolomide for Neuroendocrine Cancers Capecitabine, Temozolomide - Neuroendocrine Tumors | Phase 2 | Completed | Columbia University | 41 | 2005-08-01 | 2016-07-25 |
| Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients (Phase 2) 5 mg ilaprazole, 10 mg ilaprazole, 20 mg ilaprazole - Duodenal Ulcer | Phase 2 | Completed | Livzon Pharmaceutical Group Inc. | 235 | 2004-10-01 | 2009-08-06 |
| MK0782 + Low-Dose Aspirin 7-Day Erosion Endoscopy Study (0782-001) MK0782 - Stomach Ulcer, Duodenal Ulcer | Phase 2 | Completed | Merck Sharp & Dohme LLC | 462 | 2004-06-01 | 2015-06-11 |
| Pepsinogens as the Early Marker of H. Pylori Eradication serum pepsinogen, urea breath test - H. Pylori Infection, Gastric Ulcer | Phase 2 | Completed | Hamamatsu University | 2001-06-01 | 2006-02-01 | |
| Study to Assess the Efficacy and Safety of Somatostatin in the Treatment of Acute Severe Upper Gastrointestinal Bleeding Somatostatin UCB (drug) - Peptic Ulcer | Phase 2 | Completed | UCB Pharma | 370 | 2000-09-01 | 2012-09-18 |
Showing 20 of 23. Sign in to see all of them.
Stomach Ulcer (6) · Duodenal Ulcer (5) · Peptic Ulcer (5) · Zollinger-Ellison Syndrome (5) · Esophagitis, Peptic (4) · Gastrinoma (3) · Adenoma, Islet Cell (2) · Gastroesophageal Reflux (2) · Somatostatinoma (2) · Adenoma (1) · Adenomatous Polyposis Coli (1) · Adenomatous Polyps (1) · Carcinoid Tumor (1) · Carcinoma, Medullary (1) · Digestive System Diseases (1)
Digestive System Diseases (22) · Gastrointestinal Diseases (22) · Intestinal Diseases (22) · Stomach Diseases (22) · Peptic Ulcer (17) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Neoplasms by Site (6) · Neoplasms, Glandular and Epithelial (6) · Digestive System Neoplasms (5) · Endocrine Gland Neoplasms (5) · Endocrine System Diseases (5) · Gastroenteritis (5) · Gastrointestinal Neoplasms (5)
Rabeprazole (5) · Esomeprazole (2) · Naproxen (2) · Omeprazole (2) · ilaprazole (2) · 2-(6-methoxy-napthalen-2-yl)-propionic acid 4-thiocarbamoyl-phenyl ester (1) · Capecitabine (1) · Carbohydrates (1) · Celecoxib (1) · Clopidogrel (1) · Doxorubicin (1) · Fluorouracil (1) · Interferons (1) · Lansoprazole (1) · Pantoprazole (1)
Eisai Co., Ltd. (3) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (3) · Livzon Pharmaceutical Group Inc. (2) · Antibe Therapeutics Inc. (1) · Columbia University (1) · Federal University of Mato Grosso (1) · Hamamatsu University (1) · Jiangsu Sinorda Biomedicine Co., Ltd (1) · Kaohsiung Veterans General Hospital. (1) · King Chulalongkorn Memorial Hospital (1) · Logical Therapeutics (1) · Merck Sharp & Dohme LLC (1) · National Cancer Institute (NCI) (1) · PharmaKing (1) · Radboud University Medical Center (1)
United States (6) · Japan (5) · China (2) · South Korea (2) · Belgium (1) · Brazil (1) · Canada (1) · France (1) · Greece (1) · Hungary (1) · Netherlands (1) · Poland (1) · Spain (1) · Taiwan (1) · Thailand (1)
Nobuyuki Sugisaki (2) · Bjorn WH van Heumen, MD (1) · Deepen Patel, MD (1) · Ellen Kampman, Ph D (1) · Fokko M Nagengast, MD, Ph D (1) · James Yao (1) · Jay L Goldstein, MD (1) · Kwok-Hung Lai, MD (1) · Myung Gyy Choi, M.D., Ph.D. (1) · Naohito Shirai, MD., PhD. (1) · Paul E Oberstein, MD (1) · Pingsheng Hu, Ph.D (1) · S R Lin, M.D (1)
PMID 20679904, PMID 21144850, PMID 23919274, PMID 24245549, PMID 25956795, PMID 30919492, PMID 38910891, PMID 39836012
N01CM62202 (1), P30CA016672 (1), U01CA062490 (1)